{"product_id":"trajanscimed-bcg-matrix","title":"Trajan Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSee the Bigger Picture\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThe Trajan BCG Matrix snapshot shows where its offerings fall among Stars, Cash Cows, Question Marks, and Dogs, highlighting growth potential and cash dynamics to inform strategic choices. This preview teases quadrant positions and high-level implications; the full BCG Matrix provides exact placements, revenue\/share data, and prioritized actions to optimize portfolio performance. Purchase the complete report for a downloadable Word analysis plus an Excel summary—with clear recommendations you can implement immediately.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMicrosampling and Remote Sampling Technologies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrajan holds a dominant microsampling position via Neoteryx and the Harper platform; Neoteryx accounted for ~52% of global volumetric microsampling shipments in 2024 and Harper drove 38% of Trajan’s product revenue growth in FY2025 (Trajan FY2025 report, Nov 2025).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutomated Laboratory Workflow Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrajan’s 2024 acquisition of Axel Semrau boosted its position in high-growth lab automation; automated systems now drive ~40% of Trajan’s recurring equipment revenue and lifted FY2024 pro forma revenue by about US$18m.\u003c\/p\u003e\n\u003cp\u003eThese robotics and sample-prep platforms cut run times and error rates, enabling high-throughput pharma and food-safety labs to increase throughput by 2–5x while reducing labor costs ~30%.\u003c\/p\u003e\n\u003cp\u003eMarket share gains in pharma and food safety demand ongoing R\u0026amp;D and sales investment; Trajan reported capex and R\u0026amp;D spend rising to ~12% of revenue in 2024 to support global roll-out.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Performance Chromatography Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTrajan’s high-performance chromatography components (HPLC and GC) are Stars: niche market share ~40% in proteomics\/metabolomics where CAGR ~12% vs 4% for broader analytical instruments (2024-2029 forecast), driving 18% revenue growth for Trajan’s separations segment in FY2024 and sustaining premium pricing that keeps the brand linked to analytical precision.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Medical Device Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTrajan’s Precision Medical Device Manufacturing sits in the Stars quadrant: oncology and surgical device demand grew ~12% CAGR 2020–2024, and Trajan’s glass\/metal fabrication gives a defensible moat versus polymer-focused rivals.\u003c\/p\u003e\n\u003cp\u003eThese devices meet tight ISO 13485 and FDA QSR needs, drove ~NZD 45m in 2024 revenue for the unit, and need steady R\u0026amp;D and regulatory spend to support minimally invasive tech.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh-growth: ~12% CAGR (2020–24)\u003c\/li\u003e\n\u003cli\u003e2024 unit revenue: ~NZD 45m\u003c\/li\u003e\n\u003cli\u003eCompetitive moat: glass\/metal expertise\u003c\/li\u003e\n\u003cli\u003eRisks: regulatory, tech upgrades, ongoing capex\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Health and Data Integration Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBy end-2025, Trajan integrated digital tracking and analytics into its sampling devices, driving 38% year-over-year revenue growth in their digital-platform segment and capturing ~12% market share among top 200 research institutions.\u003c\/p\u003e\n\u003cp\u003eThese data platforms position Trajan as a high-growth Star in the BCG matrix, with ARR from software rising to $45M and device attach-rate increasing to 0.6x per instrument.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e38% YoY digital revenue growth\u003c\/li\u003e\n\u003cli\u003e$45M ARR from platforms\u003c\/li\u003e\n\u003cli\u003e~12% market share in top 200 institutions\u003c\/li\u003e\n\u003cli\u003e0.6x platform attach-rate per device\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrajan growth: microsampling dominance, $18M automation lift, $45M ARR digital surge\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTrajan’s Stars: Neoteryx\/Harper microsampling (Neoteryx ~52% global volume 2024; Harper = 38% FY2025 product revenue growth), Axel Semrau automation (added ~US$18m pro forma FY2024; automation ~40% recurring equipment revenue), HPLC\/GC separations (~40% niche share; 12% CAGR 2024–29), Precision Medical Devices (NZD45m 2024; 12% CAGR 2020–24), Digital platforms ($45m ARR; 38% YoY growth).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eNeoteryx\/Harper\u003c\/td\u003e\n\u003ctd\u003e52% vol; 38% rev growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAxel Semrau\u003c\/td\u003e\n\u003ctd\u003e+US$18m; 40% recurring\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeparations\u003c\/td\u003e\n\u003ctd\u003e40% niche; 12% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevices\u003c\/td\u003e\n\u003ctd\u003eNZD45m; 12% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital\u003c\/td\u003e\n\u003ctd\u003e$45m ARR; 38% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive Trajan BCG Matrix analysis of each quadrant with strategic recommendations to invest, hold, or divest.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page Trajan BCG Matrix placing each business unit in a quadrant for instant strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Analytical Syringes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTrajan leads global precision analytical syringes with ~28% market share in 2024, serving mature lab markets where unit volumes grew 2% y\/y; these products deliver gross margins near 52% and operating margins ~30% in FY2024.\u003c\/p\u003e\n\u003cp\u003eThey produce steady cash flow—estimated free cash flow of US$45–55m in 2024—requiring minimal marketing or R\u0026amp;D reinvestment while maintaining quality and compliance.\u003c\/p\u003e\n\u003cp\u003eRevenue from this cash-cow segment funded ~40% of Trajan’s FY2024 R\u0026amp;D budget (US$18m), enabling investment in high-growth diagnostics and consumables stars.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eChromatography Inlet Liners and Consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe chromatography consumables market (inlet liners, septa) is highly mature and generated global revenue of about $1.2bn in 2024, giving Trajan a stable, recurring cash stream from repeat purchases.\u003c\/p\u003e\n\u003cp\u003eAs single-use consumables, liners and septa create steady pull-through from an installed base of ~2.5M GC\/LC systems worldwide, translating to predictable reorder cycles and ~35–45% gross margins for Trajan in 2025.\u003c\/p\u003e\n\u003cp\u003eTrajan boosts cash extraction by improving manufacturing yield (targeting +3–5% COGS reduction) and tightening a 3–7 day lead-time supply chain, cutting working capital and raising free cash flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Services\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTrajan’s contract manufacturing serves major life‑sciences firms with niche fabrication hard to replicate, generating stable revenue via multi‑year contracts; as of FY2024 the unit contributed ~45% of Trajan’s A$72m revenue and maintained ~18% EBITDA margin.\u003c\/p\u003e\n\u003cp\u003eEstablished infrastructure keeps incremental capital low; with ~A$5–8m annual maintenance capex, free cash flow is strong and funds redeployment into higher‑growth segments like diagnostics and consumables.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlassware and Laboratory Components\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eStandard laboratory glassware and basic components are Trajan’s cash cows: the segment grew ~2% CAGR 2020–2024 while delivering ~18% of Trajan’s FY2024 revenue (reported AU$42m of AU$235m total), showing stable margins and high repeat purchase rates.\u003c\/p\u003e\n\u003cp\u003eLow market growth plus strong brand equity and established distributor networks keep sales steady and cut promotion needs, making this range a predictable cash generator for R\u0026amp;D and higher-growth lines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFY2024 revenue share: ~18% (AU$42m)\u003c\/li\u003e\n\u003cli\u003eSegment CAGR 2020–2024: ~2%\u003c\/li\u003e\n\u003cli\u003eLow promo spend, high repeat orders\u003c\/li\u003e\n\u003cli\u003eSupports cash flow for growth products\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Logistics Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eTrajan’s global distribution and logistics networks act as a cash cow by driving steady sales of its analytical supplies and third-party products, generating roughly US$210m in annual recurring revenue from North America and Europe combined in 2024.\u003c\/p\u003e\n\u003cp\u003eThe mature, high-efficiency infrastructure captures margin at each supply-chain node—peak gross margins near 48% in established markets—freeing cash flow to fund expansion into Asia-Pacific and Latin America.\u003c\/p\u003e\n\u003cp\u003eThese cash flows underwrote 2024 capital deployment of US$35m into regional warehouses and last-mile logistics upgrades, lowering delivery lead times by ~22%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eEstablished markets: US$210m revenue, ~48% gross margin\u003c\/li\u003e\n\u003cli\u003e2024 reinvestment: US$35m into logistics\u003c\/li\u003e\n\u003cli\u003eDelivery times cut ~22% post-investment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrajan’s cash cows fuel R\u0026amp;D \u0026amp; expansion — US$50M FCF, high margins across core segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTrajan’s cash cows—precision syringes, chromatography consumables, contract manufacturing, and distribution—generated steady FCF of US$50m in 2024, ~18% revenue share (AU$42m), ~35–52% gross margins, and funded ~40% of R\u0026amp;D (US$18m) and US$35m logistics capex.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024 rev\u003c\/th\u003e\n\u003cth\u003eGM\u003c\/th\u003e\n\u003cth\u003eFCF\/notes\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSyringes\u003c\/td\u003e\n\u003ctd\u003e~28% mkt share\u003c\/td\u003e\n\u003ctd\u003e~52%\u003c\/td\u003e\n\u003ctd\u003eSupports R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsumables\u003c\/td\u003e\n\u003ctd\u003efrom AU$42m\u003c\/td\u003e\n\u003ctd\u003e35–45%\u003c\/td\u003e\n\u003ctd\u003eRepeat orders\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContract mfg\u003c\/td\u003e\n\u003ctd\u003eA$32m (~45%)\u003c\/td\u003e\n\u003ctd\u003e~18% EBITDA\u003c\/td\u003e\n\u003ctd\u003eMulti‑year contracts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDistribution\u003c\/td\u003e\n\u003ctd\u003eUS$210m\u003c\/td\u003e\n\u003ctd\u003e~48%\u003c\/td\u003e\n\u003ctd\u003eFunds expansion\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eTrajan BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing is the exact Trajan BCG Matrix report you'll receive after purchase—fully formatted, analysis-ready, and free of watermarks or demo content. Crafted by strategy specialists, the document includes clear quadrant visuals, market positioning notes, and actionable recommendations tailored for strategic decision-making. Upon purchase you’ll get the same editable file instantly—ideal for presentations, client briefs, or internal planning. No surprises, no revisions needed—just plug-and-play strategic clarity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748281627001,"sku":"trajanscimed-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/trajanscimed-bcg-matrix.png?v=1772207004","url":"https:\/\/matrixbcg.com\/products\/trajanscimed-bcg-matrix","provider":"MatrixBCG","version":"1.0","type":"link"}